418.62 0.00 (0.00%)
After hours: 4:28PM EST
|Bid||415.02 x 1100|
|Ask||421.00 x 1000|
|Day's Range||415.59 - 422.61|
|52 Week Range||281.89 - 431.32|
|Beta (3Y Monthly)||0.97|
|PE Ratio (TTM)||19.66|
|Earnings Date||Feb 6, 2019 - Feb 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||427.00|
Pfizer (PFE) and Eli Lilly (LLY) announce that the higher dose of their investigational pain candidate, tanezumab, significantly reduces chronic low back pain in a late-stage study.
Is Teva Pharmaceutical an Attractive Pick This February?(Continued from Prior Part)Growth driversOn its fourth-quarter earnings conference call, Teva Pharmaceutical (TEVA) highlighted Ajovy and Austedo as its key growth drivers for 2019.Copaxone
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced two important legal developments invalidating Immunex patents with functional claims to antibodies that target human interleukin-4 receptors (IL-4R). Earlier today, the Opposition Division of the European Patent Office (EPO) revoked Immunex's European Patent No. 2,990,420 in its entirety because the claims were invalid for insufficiency of disclosure. This follows a decision yesterday by the Patent Trial and Appeal Board (PTAB) of the U.S. Patent & Trademark Office (USPTO) to invalidate all 17 claims of Immunex's U.S. Patent No. 8,679,487 as obvious.
TARRYTOWN, N.Y. , Feb. 14, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast its management presentation at the Cowen 39 th Annual Healthcare Conference at 11:20 a.m. ET ...
Key highlights of the week were fourth-quarter results from Regeneron Pharmaceuticals and Ligand Pharmaceuticals along with other regulatory and pipeline updates.
Sanofi (SNY) and Regeneron (REGN) announce a 60% cut in the U.S. list price of their cholesterol lowering drug, Praluent to improve access and affordability of the product.
NEW YORK, Feb. 12, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
Regeneron spent $383.1 million on capital expenditures last year, an increase of $110 million from 2017.
A growing effort to push back on price increases is affecting pharmaceutical companies. Regeneron and Sanofi are the latest to announce a cut, for the cholesterol drug Praluent.
Sanofi SA and Regeneron Pharmaceuticals Inc said on Monday that they will slash the U.S. list price of their potent but expensive cholesterol fighter Praluent by 60 percent, as the drugmakers follow a similar move by rival Amgen Inc in hopes of increasing use of the drug. The new list price for Praluent will be $5,850 (£4,533) a year, matching the price Amgen set when it lowered the list of its competing drug, Repatha, in October.
BRIDGEWATER, N.J. and TARRYTOWN, N.Y., Feb. 11, 2019 /PRNewswire/ -- Praluent® (alirocumab) will be made available at a new reduced U.S. list price of $5,850 annually, a 60% reduction from the original price, for both the 75 mg and 150 mg doses, beginning in early March. The new lower-priced Praluent is expected to result in lower patient out-of-pocket costs and represents another step in the companies' efforts to help improve patient affordability and access. This follows an earlier announcement in March 2018, when Sanofi and Regeneron committed to lower the U.S. net price for payers in return for helping to reduce burdensome access barriers for appropriate patients.
Sanofi SA and Regeneron Pharmaceuticals Inc said on Monday that they will slash the U.S. list price of their potent but expensive cholesterol fighter Praluent by 60 percent, as the drugmakers follow a similar move by rival Amgen Inc in hopes of increasing use of the drug. The new list price for Praluent will be $5,850 a year, matching the price Amgen set when it lowered the list of its competing drug, Repatha, in October.
The new lower-priced Praluent is expected to result in lower patient out-of-pocket costs and represents another step in the companies' efforts to help improve patient affordability and access. This follows an earlier announcement in March 2018, when Regeneron and Sanofi committed to lower the U.S. net price for payers in return for helping to reduce burdensome access barriers for appropriate patients.
are slashing the list price of anti-cholesterol drug Praluent by 60 per cent, as the drugmakers respond to pressure from US health insurers and pharmacy benefit managers reluctant to adopt the costly medicine. Praluent will have a list price of $5,850 a year from early March, down from about $14,000 previously. The price cut is designed to make the drug more affordable for older patients using Medicare, cutting out-of-pocket costs to between $25 and $150 a month, depending on the plan.
TARRYTOWN, N.Y. , Feb. 9, 2019 /PRNewswire/ -- Trial showed that early intervention with EYLEA improved diabetic retinopathy severity and prevented serious vision-threatening complications EYLEA diabetic ...
The Zacks Analyst Blog Highlights: Chevron, CSX, Regeneron, Capital One and Canadian National
Regeneron Pharmaceuticals Inc NASDAQ/NGS:REGNView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for REGN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting REGN. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding REGN totaled $12.17 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! As Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) released itsRead More...
Regeneron Pharmaceuticals Inc is an integrated biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron Pharmaceuticals Inc had annual average EBITDA growth of 31.70% over the past five years.
Sanofi (SNY) beat estimates for earnings and missed the same for sales in the fourth quarter. The Specialty Care unit drove top-line growth.